Compare OCS & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCS | SDHY |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.3M | 377.3M |
| IPO Year | 2022 | N/A |
| Metric | OCS | SDHY |
|---|---|---|
| Price | $7.50 | $15.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $35.89 | N/A |
| AVG Volume (30 Days) | ★ 253.1K | 61.9K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $389.20 | N/A |
| P/E Ratio | ★ N/A | $14.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.78 | $14.67 |
| 52 Week High | $34.48 | $16.89 |
| Indicator | OCS | SDHY |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 41.10 |
| Support Level | $6.95 | $14.87 |
| Resistance Level | $8.84 | $16.34 |
| Average True Range (ATR) | 0.65 | 0.29 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 33.83 | 10.94 |
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.